[ad_1]
When not busy making an attempt to resurrect the wooly mammoth, geneticist George Church spends his time launching new biotech corporations at a tempo practically on par with SpaceX sending rockets into house. Eventually rely, he had co-founded or in any other case helped kickstart about 50 completely different corporations – a lot of which have gained some quantity of traction. As an example, Ginkgo Bioworks (DNA) acquired considered one of his very first ventures, an artificial biology startup referred to as Gen9 that we lined on the time. In truth, we’ve written about plenty of the Harvard professor’s many companies, and even held shares in one other early enterprise, Editas Medication (EDIT), earlier than exiting our place in 2022.
One other considered one of Church’s earliest startups was an organization referred to as ReadCoor whose intellectual property (IP) would finally grow to be a key know-how that’s at the moment serving to gas progress for 10X Genomics (TXG). The biotech firm just lately launched its 2023 year-end outcomes. Income climbed 20% year-over-year to greater than $618 million after progress hit a wall the prior yr in 2022. New product platforms are serving to revive progress, although the corporate’s flagship platform continues to be flagging and gross margins are nonetheless shrinking. Let
[ad_2]
Source link